Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Uvax Bio General Information
The UVAX-1107 protein nanoparticle vaccine was reported as safe and well-tolerated in healthy volunteers. After two priming doses, 100% of subjects showed robust vaccine-matched IgG antibody responses. The company has begun Phase 1 clinical trials for its HIV-1 vaccine candidates (UVAX-1107 and UVAX-1197) in Australia.
Contact Information
Drug Pipeline
HIV-1 vaccine
Phase 1Key Partnerships
National Institutes of Health (NIH), National Institute for Innovation in Manufacturing Biopharmaceuticals, University of Delaware, Scripps Research
Uvax Bio Funding
No funding data available
To view Uvax Bio's complete valuation and funding history, request access »